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Response to Zhang et al. (2005)
Loss-of-Function Mutation in Tryptophan
Hydroxylase-2 Identified in Unipolar
Major Depression. Neuron 45, 11–16
We genotyped 1023 samples from human subjects with
a diagnosis of unipolar depression for the neuronal
tryptophan hydroxylase-2 (TPH2) mutation reported by
Zhang et al. (2005). With the use of a Taqman 50 nuclease
assay (ABI, Assay by Design) we genotyped the entire
Genetics of Response to Antidepressant Drugs (GRAD)
sample at the G1463A TPH2 mutation and did not
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Zhang and colleagues reported the G1463A variant
(c.1322G>A) that predicted an amino acid substitution
at a highly conserved position in tryptophan hydroxy-
lase-2 (TPH2) (p.Arg441His). Functional analysis of
441His showed an w80% loss in serotonin production
when expressed in PC12 cells. The authors’ genetic
data showed the presence of the 1463 A-allele in 9 of
87 elderly unipolar affective disorder (UP) patients (>60
years) and in 3 of 219 healthy control individuals.
Based on these finding, we genotyped the G1463A
variant in two large patient-control samples obtained in
northern-Sweden and Belgium. The northern-Swedish
sample was comprised of 135 UP patients (87 females,
48 males, mean age at inclusion was 56.6 years), 182 bi-
polar (BP) patients (96 females, 86 males, mean age at
inclusion was 56.3 years), and 364 healthy age-, gen-
der-, and ethnicity-matched control individuals. The
Belgian sample consisted of 182 UP patients (121 fe-
males, 61 males, mean age at inclusion was 46.6 years),
182 BP patients (99 females, 83 males, mean age at in-
clusion was 45.3 years) and 364 healthy age-, gender-,
and ethnicity-matched control individuals. Genotyping
was performed by pyrosequencing on a PSQTMHS96
pyrosequencer (http://www.pyrosequencing.com/) with
the use of 50-bio-GTTTATTCTGCAGGGACTTTGC-30 and
50-CGAAGGTCCTGCACCACA-30 as PCR primers and
50-GAAGTATACTGAGAAGG-30 as reverse sequencing
primer. We did not observe the A-allele in any of the pa-
tients nor in the control individuals. To confirm the va-
lidity of our pyrosequencing assay, we subsequently
sequenced genomic DNA of all patients and control indi-
viduals by using PCR-based direct sequencing with pri-
mers 50-AGCCTTTGACCCAAAGACAA-30 (forward) and
50-AGATCATGCTGGCAACAACA-30 (reverse). Sequence
trace files were analyzed for the occurrence of the
G1463A variant with novoSNP (Weckx et al., 2005) and
visual inspection. The sequencing data confirmed the
absence of the 1463A-allele in all subjects. This unex-
pected absence of the TPH2 1463A-allele in 681 patients
with affective disorders and 728 control individuals from
two independent patient-control cohorts obtained from
northern-Sweden and Belgium raises doubts about the
true nature of this polymorphism. Even if the A-allele
was rare in our Caucasian populations, it would have
a frequency of <1/2818 chromosomes, or <0.035%.
This contradicts the high prevalence of this polymor-
phism in 15/662 chromosomes (2.3%) in Caucasians
reported by Zhang et al. (2005). Because the authors
selected older patients (>60 years) for their study, we
cannot exclude that the A-allele is enriched due to an as-
sociated protective survival effect. However, because
the frequency of affective disorders is very similar world-
wide and no studies have reported increased survival
due to reduced serotonin levels, this assumption is un-
likely to explain their genetic data. Furthermore, 7 of the
9 depressed patients with the 1463A-allele failed to re-
spond to SSRI treatment, while 2 patients required highconcentration. Therefore, it seems more plausible that
the observed high frequency of the 1463A-allele reported
by Zhang et al. (2005) is the result of severe patient pop-
ulation stratification based on age of inclusion and/or
SSRI treatment failure. Anyway, even with the strong
functional data of which we do not doubt the quality, the
report of a functional relevant genetic THP2 polymor-
phism associated with affective disorders is at this stage
uncertainand needs tobe replicated independently. Even
more, recent guidelines for genetic association studies
in complex diseases are firm when it comes to sample
sizes and replication, even for functionally relevant var-
iants in important candidate genes, and therefore war-
rant genotyping the G1463A variant in large patient-
control populations (Smyth et al., 2005; Qu et al., 2005).
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